Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab

Hematology Reports

Volumn 8, Issue 3, 2016, Pages 44-47

  Raufi, Alexander G ^a   Scott, Shruti ^a   Darwish, Omar ^a   Harley, Kevin ^a   Kahlon, Kanwarpal ^a   Desai, Sheetal ^a   Lu, Yuxin ^a   Tran, Minh Ha ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atypical hemolytic uremic syndrome; Lupus nephritis; Microangiopathic hemolytic anemia; Thrombotic microangiopathy

Indexed keywords

ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; BILIRUBIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LACTATE DEHYDROGENASE; MYCOPHENOLIC ACID; RITUXIMAB;

ABDOMINAL DISCOMFORT; ABDOMINAL TENDERNESS; ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; AXILLARY LYMPH NODE; CAPILLARY PROLIFERATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DRUG MEGADOSE; DYSPNEA; ECHOGRAPHY; ERYTHROCYTE TRANSFUSION; FACE EDEMA; FEMALE; HEADACHE; HEMATOCRIT; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPOCOMPLEMENTEMIA; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE COUNT; LUNG EDEMA; LUNG EMBOLISM; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHADENOPATHY; MEDIASTINUM LYMPH NODE; MENINGOCOCCOSIS; METACARPOPHALANGEAL JOINT; MORNING STIFFNESS; MYALGIA; NAUSEA; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PLASMA EXCHANGE; PLEURA EFFUSION; PROTEINURIA; PROXIMAL INTERPHALANGEAL JOINT; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREA NITROGEN BLOOD LEVEL; URINALYSIS; VIETNAMESE; VOMITING;

EID: 84990829817     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2016.6625     Document Type: Article

References (20)

1. Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;43:976-81.
2. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:61.
3. George JN, Nester CM. Syndromes of thrombotic microangiopathy. New Engl J Med 2014;371:654-61.
4. Davin, JC, van de Kar NCAJ. Advances and challenges in the management of complement- mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-81.
5. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-51.
6. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007;18:2392-401.
7. Nester CM, Barbour T, Rodriguez de Cordoba S, et al. Atypical HUS: state of the art. Mol Immunol 2015;67:31-41.
8. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-81.
9. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosis revisited. J Am Soc Nephrol 2004;15:241-51.
10. Gunnarsson I, Jonsdottir T. Rituximab treatment in lupus nephritis – where do we stand? Lupus 2013;22:381-1.
11. Coppo R, Peruzzi L, Amore A, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-71.
12. Samson M, Audia S, Leguy V, et al. Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange. Int Med J 2012;42:95-1.
13. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice. Evidencebased approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apheresis 2013;28:145-281.
14. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015;65:127-31.
15. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 2015;54:2286-1.
16. Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by shiga toxin promotes exuberant c3a formation that triggers microvascular thrombosis. J Immunol 2011;187:172-81.
17. Conway EM. HUS and the case for complement. Blood 2015;126:2085-91.
18. Cugno M, Gualtierotti R, Possenti I, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-1.
19. Ardissino G, Testa S, Possenti I, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014;64:633-1.
20. Gatault P, Brachet G, Ternant D, et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs 2015;9:1205-11.